Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Paul, Reddell"'
Autor:
Frank Dickson Antwi, Tufaha Awad, Meghan Larin, Kate Heesom, Phil Lewis, Paul Reddell, Zaruhi Poghosyan, Sharon Dewitt, Ryan Moseley, Vera Knäuper
Publikováno v:
Cells, Vol 13, Iss 11, p 982 (2024)
Tigilanol tiglate (TT, also known as EBC-46) is a novel, plant-derived diterpene ester possessing anticancer and wound-healing properties. Here, we show that TT-evoked PKC-dependent S985 phosphorylation of the tyrosine kinase MET leads to subsequent
Externí odkaz:
https://doaj.org/article/b063e5e14f0d4f9c81d992bdcf3a437c
Autor:
Wenya Xue, Manon F. Pritchard, Saira Khan, Lydia C. Powell, Joana Stokniene, Jingxiang Wu, Nicholas Claydon, Paul Reddell, David W. Thomas, Katja E. Hill
Publikováno v:
Journal of Oral Microbiology, Vol 15, Iss 1 (2023)
ABSTRACTBackground Peri-implantitis has become an inexorable clinical challenge in implantology. Topical immunomodulatory epoxy-tiglianes (EBCs), derived from the Queensland blushwood tree, which induce remodeling and resolve dermal infection via ind
Externí odkaz:
https://doaj.org/article/6ffefe779bfc40e689eabbcbca512010
Autor:
Graham K. Brown, Jessica R. Finlay, Rodney C. Straw, Joy Y. Ziea, Becky Leung, Kathleen O'Connell, Maurine J. Thomson, Justine E. Campbell, Pamela D. Jones, Paul Reddell
Publikováno v:
Frontiers in Veterinary Science, Vol 9 (2022)
Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of de novo/non-metastatic origin are reported in a proportion of the patient population. Where there is no evi
Externí odkaz:
https://doaj.org/article/07a76564ce0745ec831b10b7fb56ca25
Autor:
Thomas R. De Ridder, Justine E. Campbell, Cheryl Burke‐Schwarz, David Clegg, Emily L. Elliot, Samuel Geller, Wendy Kozak, Stephen T. Pittenger, Jennifer B. Pruitt, Jocelyn Riehl, Julie White, Melissa L. Wiest, Chad M. Johannes, John Morton, Pamela D. Jones, Peter F. Schmidt, Victoria Gordon, Paul Reddell
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 35, Iss 1, Pp 415-429 (2021)
Abstract Objective To evaluate the efficacy and safety of tigilanol tiglate (TT) for local intratumoral treatment of mast cell tumors (MCTs) in dogs. Methods A randomized controlled clinical study in 2 phases involving 123 dogs with cytologically dia
Externí odkaz:
https://doaj.org/article/1df0a2eb05904e1abae36124d5866f9c
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 35, Iss 1, Pp 451-455 (2021)
Abstract Background Tigilanol tiglate (TT) is a novel small molecule approved by the European Medicines Agency for intratumoral treatment of mast cell tumors (MCTs) in dogs. In a randomized controlled clinical efficacy and safety study in the United
Externí odkaz:
https://doaj.org/article/30866ecda9b14defb6f8f3736644451e
Autor:
Paul Reddell, Thomas R. De Ridder, John M. Morton, Pamela D. Jones, Justine E. Campbell, Graham Brown, Chad M. Johannes, Peter F. Schmidt, Victoria Gordon
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 35, Iss 1, Pp 430-441 (2021)
Abstract Background Tigilanol tiglate (TT) is a novel small molecule for intratumoral treatment of nonmetastatic mast cell tumors (MCTs) in dogs. In a randomized controlled clinical study, 75% of dogs that received a single TT treatment achieved comp
Externí odkaz:
https://doaj.org/article/ce30c3d533e44be39a8c2c5a3b666f9e
Publikováno v:
Frontiers in Veterinary Science, Vol 8 (2021)
Tigilanol tiglate (TT) is a novel small molecule registered as a veterinary pharmaceutical for intratumoural treatment of canine mast cell tumours (MCTs). The drug has a multifactorial mode of action resulting in rapid destruction of the treated tumo
Externí odkaz:
https://doaj.org/article/1847ab11309d47bab20a91570625cff3
Autor:
Graham K. Brown, Justine E. Campbell, Pamela D. Jones, Thomas R. De Ridder, Paul Reddell, Chad M. Johannes
Publikováno v:
Frontiers in Veterinary Science, Vol 8 (2021)
Canine high-grade mast cell tumours (HGMCT) are associated with a poor prognosis, are inherently more invasive, and have higher rates of local recurrence. The primary aim of this retrospective study was to assess the efficacy of intratumoural tigilan
Externí odkaz:
https://doaj.org/article/588245b789e64fd7ac070eb92bf27d65
Publikováno v:
Frontiers in Veterinary Science, Vol 7 (2020)
Tigilanol tiglate is a novel small molecule approved as a veterinary pharmaceutical in Europe for intratumoural treatment of non-metastatic, non-resectable canine mast cell tumors. The drug has a “tumor agnostic” mode of action associated with in
Externí odkaz:
https://doaj.org/article/314ac6f23e234b2e8a2a0cd48c3b2e06
Autor:
Jane Miller, Justine Campbell, Andrew Blum, Paul Reddell, Victoria Gordon, Peter Schmidt, Stewart Lowden
Publikováno v:
Frontiers in Veterinary Science, Vol 6 (2019)
Mast cell tumor (MCT) is the most common cutaneous neoplasm in dogs and wide surgical resection is the current first-line treatment. However, recurrence is common and often requires more specialist and expensive therapies. Tigilanol tiglate is a nove
Externí odkaz:
https://doaj.org/article/4fab483a439f43eab9e793c89fa120d7